{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T17:54:59Z","timestamp":1784829299618,"version":"3.55.0"},"reference-count":116,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"am","delay-in-days":354,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.clml.2022.12.014","type":"journal-article","created":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T21:08:33Z","timestamp":1672952913000},"page":"219-231","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["SOHO State of the Art Updates and Next Questions: Novel Therapeutic Strategies in Development for Myelofibrosis"],"prefix":"10.1016","volume":"23","author":[{"given":"Helen T.","family":"Chifotides","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Masarova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6912-8569","authenticated-orcid":false,"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.12.014_bib0001","series-title":"The MD Anderson Manual of Medical Oncology","first-page":"119","article-title":"Philadelphia chromosome-negative myeloproliferative neoplasms (Chapter 6)","author":"Bose","year":"2022"},{"key":"10.1016\/j.clml.2022.12.014_bib0002","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1159\/000512929","article-title":"Accelerated phase of myeloproliferative neoplasms","volume":"144","author":"Shahin","year":"2021","journal-title":"Acta Haematologica"},{"key":"10.1016\/j.clml.2022.12.014_bib0003","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/bs.ircmb.2021.02.008","article-title":"Mutational landscape of blast phase myeloproliferative neoplasms (BP-MPN) and antecedent MPN","volume":"366","author":"Pasca","year":"2022","journal-title":"Int Rev Cell Mol Biol."},{"key":"10.1016\/j.clml.2022.12.014_bib0004","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood.2019000943","article-title":"Leukemia secondary to myeloproliferative neoplasms","volume":"136","author":"Dunbar","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.12.014_bib0005","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-017-0527-7","article-title":"Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J Hematol Oncol."},{"key":"10.1016\/j.clml.2022.12.014_bib0006","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1002\/cncr.34103","article-title":"Improved survival of patients with myelofibrosis in the last decade: Single-center experience","volume":"128","author":"Masarova","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2022.12.014_bib0007","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00277-021-04682-x","article-title":"Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval","volume":"101","author":"Verstovsek","year":"2022","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2022.12.014_bib0008","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1182\/bloodadvances.2021006006","article-title":"Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST study","volume":"6","author":"Guglielmelli","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2022.12.014_bib0009","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1182\/bloodadvances.2022007230","article-title":"Does ruxolitinib really prolong survival in individuals with myelofibrosis? The never-ending story","volume":"6","author":"Barosi","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2022.12.014_bib0010","doi-asserted-by":"crossref","DOI":"10.1177\/20406207221118429","article-title":"Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50 x 109\/L to <100 x 109\/L) at baseline: the final analysis of EXPAND","volume":"13","author":"Guglielmelli","year":"2022","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.clml.2022.12.014_bib0011","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.12.014_bib0012","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.clml.2022.12.014_bib0013","doi-asserted-by":"crossref","first-page":"E314","DOI":"10.1016\/S2352-3026(17)30088-1","article-title":"Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study","volume":"4","author":"Harrison","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2022.12.014_bib0014","first-page":"S203","article-title":"Overall and progression-free survival in patients treated with fedratinib as first-line myelofibrosis (MF) therapy and after prior ruxolitinib (RUX): results from the JAKARTA and JAKARTA-2 trials","volume":"5","author":"Harrison","year":"2021","journal-title":"HemaSphere"},{"key":"10.1016\/j.clml.2022.12.014_bib0015","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/ajh.25777","article-title":"Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure","volume":"95","author":"Harrison","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2022.12.014_bib0016","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s11899-018-0447-9","article-title":"Management of myelofibrosis-related cytopenias","volume":"13","author":"Bose","year":"2018","journal-title":"Curr Hematol Malig Rep."},{"key":"10.1016\/j.clml.2022.12.014_bib0017","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/HS9.0000000000000001","article-title":"Myelofibrosis-related anemia: current and emerging therapeutic strategies","volume":"1","author":"Naymagon","year":"2017","journal-title":"HemaSphere"},{"key":"10.1016\/j.clml.2022.12.014_bib0018","doi-asserted-by":"crossref","first-page":"e507","DOI":"10.1016\/j.clml.2022.01.016","article-title":"Thrombocytopenia in patients with myelofibrosis: pathogenesis, prevalence, prognostic impact, and treatment","volume":"22","author":"Sastow","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2022.12.014_bib0019","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.clml.2020.01.008","article-title":"The myelodepletive phenotype in myelofibrosis: clinical relevance and therapeutic implication","volume":"20","author":"Marcellino","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2022.12.014_bib0020","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/ejh.13005","article-title":"Significance of thrombocytopenia in patients with primary and post-essential thrombocythemia\/polycythemia vera myelofibrosis","volume":"100","author":"Masarova","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2022.12.014_bib0021","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3324\/haematol.2010.031831","article-title":"Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS","volume":"96","author":"Elena","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.12.014_bib0022","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.clml.2021.06.008","article-title":"SOHO State of the Art Updates and Next Questions: Identifying and treating \"progression\" in myelofibrosis","volume":"21","author":"Bose","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2022.12.014_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100716","article-title":"Management of challenging myelofibrosis after JAK inhibitor failure and\/or progression","volume":"42","author":"Scherber","year":"2020","journal-title":"Blood Rev"},{"key":"10.1016\/j.clml.2022.12.014_bib0024","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1182\/blood-2017-05-783225","article-title":"Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"130","author":"Newberry","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.12.014_bib0025","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/cncr.32664","article-title":"Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis","volume":"126","author":"Palandri","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2022.12.014_bib0026","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1080\/13696998.2020.1741381","article-title":"Patient characteristics and outcomes after ruxolitinib discontinuation in patients with myelofibrosis","volume":"23","author":"Mascarenhas","year":"2020","journal-title":"J Med Econ"},{"key":"10.1016\/j.clml.2022.12.014_bib0027","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/ejh.13330","article-title":"Survival outcomes in myelofibrosis patients treated with ruxolitinib: a population-based cohort study in Sweden and Norway","volume":"103","author":"Schain","year":"2019","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2022.12.014_bib0028","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1002\/cncr.34222","article-title":"The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes","volume":"128","author":"Mascarenhas","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2022.12.014_bib0029","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.3324\/haematol.2021.279415","article-title":"Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia","volume":"107","author":"Verstovsek","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.12.014_bib0030","first-page":"5929","article-title":"Pacritinib demonstrates spleen volume reduction in patients with myelofibrosis independent of JAK2 V617F allele burden","volume":"4","author":"Tremblay","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2022.12.014_bib0031","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.1182\/bloodadvances.2022007524","article-title":"The Odyssey of pacritinib in myelofibrosis","volume":"6","author":"Venugopal","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2022.12.014_bib0032","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1080\/17474086.2022.2112565","article-title":"Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia","volume":"15","author":"Mascarenhas","year":"2022","journal-title":"Exp Rev Hematol"},{"key":"10.1016\/j.clml.2022.12.014_bib0033","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial","volume":"4","author":"Mascarenhas","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2022.12.014_bib0034","doi-asserted-by":"crossref","first-page":"5825","DOI":"10.1182\/bloodadvances.2020003314","article-title":"Determining the recommended dose of pacritinib: Results from the PAC203 dose-finding study in advanced myelofibrosis","volume":"4","author":"Gerds","year":"2020","journal-title":"Blood Adv"},{"issue":"Suppl. 1","key":"10.1016\/j.clml.2022.12.014_bib0035","doi-asserted-by":"crossref","first-page":"9592","DOI":"10.1182\/blood-2022-163456","article-title":"PACIFICA: A randomized, controlled phase 3 study of pacritinib versus physician's choice in patients with primary or secondary myelofibrosis and severe thrombocytopenia","volume":"140","author":"Mascarenhas","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.12.014_bib0036","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.clml.2021.10.002","article-title":"SOHO State of the Art Updates and Next Questions: Novel therapies in development for myelofibrosis","volume":"22","author":"Chifotides","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2022.12.014_bib0037","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.3390\/cancers12102891","article-title":"Novel concepts of treatment for patients with myelofibrosis and related neoplasms","volume":"12","author":"Bose","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2022.12.014_bib0038","doi-asserted-by":"crossref","first-page":"e424","DOI":"10.1097\/HS9.0000000000000424","article-title":"JAK inhibition for the treatment of myelofibrosis: limitations and future perspectives","volume":"4","author":"Bose","year":"2020","journal-title":"HemaSphere"},{"key":"10.1016\/j.clml.2022.12.014_bib0039","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.2217\/fon-2022-0276","article-title":"Momelotinib for treatment of myelofibrosis with anemia","volume":"18","author":"Tremblay","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.clml.2022.12.014_bib0040","doi-asserted-by":"crossref","first-page":"129","DOI":"10.36401\/JIPO-20-36","article-title":"JAK be nimble: reviewing the development of JAK inhibitors and JAK inhibitor combinations for special populations of patients with myelofibrosis","volume":"4","author":"Kuykendall","year":"2021","journal-title":"J Immunother Precision Oncol"},{"key":"10.1016\/j.clml.2022.12.014_bib0041","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1182\/blood-2012-02-414631","article-title":"Long-term outcomes of 107 patients with myelofibrosis receiving JAK1\/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls","volume":"120","author":"Verstovsek","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.12.014_bib0042","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3324\/haematol.2014.119545","article-title":"A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis","volume":"100","author":"Vannucchi","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.12.014_bib0043","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.clml.2017.05.015","article-title":"Practical measures of clinical benefit with ruxolitinib therapy: An exploratory analysis of COMFORT-I","volume":"17","author":"Miller","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2022.12.014_bib0044","doi-asserted-by":"crossref","first-page":"e778","DOI":"10.1097\/HS9.0000000000000778","article-title":"Treating anemic patients with myelofibrosis in the new Janus kinase inhibitor era: Current evidence and real-world implications","volume":"6","author":"Gerds","year":"2022","journal-title":"HemaSphere"},{"key":"10.1016\/j.clml.2022.12.014_bib0045","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/s41375-018-0028-x","article-title":"Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients","volume":"32","author":"Nicolosi","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.12.014_bib0046","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mayocp.2011.11.001","article-title":"One thousand patients with primary myelofibrosis: The Mayo Clinic experience","volume":"87","author":"Tefferi","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2022.12.014_bib0047","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/nm.3512","article-title":"Transforming growth factor-beta superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis","volume":"20","author":"Suragani","year":"2014","journal-title":"Nat Med"},{"issue":"Suppl. 1","key":"10.1016\/j.clml.2022.12.014_bib0048","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/blood-2020-137265","article-title":"Duration of response to luspatercept in patients (pts) requiring red blood cell (RBC) transfusions with myelofibrosis (MF) \u2013 Updated data from the phase 2 ACE-536-MF-001 study","volume":"136","author":"Gerds","year":"2020","journal-title":"Blood"},{"issue":"Suppl. 2","key":"10.1016\/j.clml.2022.12.014_bib0049","first-page":"805","article-title":"Efficacy and safety of luspatercept versus placebo in patients with myeloproliferative neoplasm-associated myelofibrosis on JAK2 inhibitor therapy and requiring RBC transfusions (INDEPENDENCE trial)","volume":"6","author":"Mesa","year":"2021","journal-title":"HemaSphere"},{"key":"10.1016\/j.clml.2022.12.014_bib0050","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ccell.2017.11.009","article-title":"Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms","volume":"33","author":"Kleppe","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2022.12.014_bib0051","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1038\/s41375-021-01405-z","article-title":"Paradigm shift: combination BET and JAK inhibition in myelofibrosis","volume":"35","author":"Mascarenhas","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.12.014_bib0052","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/leu.2016.260","article-title":"BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells","volume":"31","author":"Saenz","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.12.014_bib0053","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000843684.97625.7e","article-title":"BET inhibitor pelabresib (CPI-0610) combined with ruxolitinib in patients with myelofibrosis \u2013 JAK-inhibitor na\u00efve or with suboptimal response to ruxolitinib \u2013 Preliminary data from the MANIFEST study","volume":"6","author":"Mascarenhas","year":"2022","journal-title":"HemaSphere"},{"key":"10.1016\/j.clml.2022.12.014_bib0054","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"issue":"Suppl. 1","key":"10.1016\/j.clml.2022.12.014_bib0055","doi-asserted-by":"crossref","first-page":"S362","DOI":"10.1016\/S2152-2650(21)01833-4","article-title":"Clinical benefit of pelabresib (CPI-0610) in combination with ruxolitinib in JAK inhibitor treatment na\u00efve myelofibrosis patients: Interim efficacy subgroup analysis from Arm 3 of the MANIFEST phase 2 study","volume":"21","author":"Gupta","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2022.12.014_bib0056","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.2217\/fon-2022-0484","article-title":"Phase III MANIFEST-2: pelabresib\u00a0+\u00a0ruxolitinib vs. placebo\u00a0+\u00a0ruxolitinib in JAK-inhibitor treatment-na\u00efve myelofibrosis","volume":"18","author":"Harrison","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.clml.2022.12.014_bib0057","doi-asserted-by":"crossref","first-page":"10978","DOI":"10.1111\/jcmm.15730","article-title":"Bcl-xL represents a therapeutic target in Philadelphia negative myeloproliferative neoplasms","volume":"24","author":"Petiti","year":"2020","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.clml.2022.12.014_bib0058","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/01.HS9.0000843680.94912.c5","article-title":"Navitoclax plus ruxolitinib in JAK-inhibitor na\u00efve patients with myelofibrosis: Preliminary safety and efficacy in a multicenter, open-label phase 2 study","volume":"6(S3)","author":"Passamonti","year":"2022","journal-title":"HemaSphere"},{"issue":"Suppl. 1","key":"10.1016\/j.clml.2022.12.014_bib0059","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2020-139758","article-title":"A phase 3, double-blind, placebo-controlled, randomized study evaluating navitoclax in combination with ruxolitinib in patients with myelofibrosis (TRANSFORM-1)","volume":"136","author":"Potluri","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.12.014_bib0060","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1080\/14737140.2022.2093192","article-title":"Targeting the PI3K pathway in myeloproliferative neoplasms","volume":"22","author":"Gerds","year":"2022","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.clml.2022.12.014_bib0061","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1158\/1535-7163.MCT-12-0862","article-title":"Dual PI3K\/AKT\/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells","volume":"12","author":"Fiskus","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clml.2022.12.014_bib0062","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/jcmm.12162","article-title":"Co-targeting the PI3K\/mTOR and JAK2 signaling pathways produces synergistic activity against myeloproliferative neoplasms","volume":"17","author":"Bartalucci","year":"2013","journal-title":"J Cell Mol Med"},{"issue":"Suppl. 1","key":"10.1016\/j.clml.2022.12.014_bib0064","doi-asserted-by":"crossref","first-page":"TPS7058","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS7058","article-title":"A phase 3, randomized, double-blind, placebo-controlled study of ruxolitinib plus parsaclisib in patients with JAK- and PI3K-inhibitor treatment-na\u00efve myelofibrosis","volume":"39","author":"Yacoub","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.12.014_bib0065","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.celrep.2013.10.038","article-title":"Combined targeting of JAK2 and Bcl-2\/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors","volume":"5","author":"Waibel","year":"2013","journal-title":"Cell Reports"},{"key":"10.1016\/j.clml.2022.12.014_bib0066","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1200\/JCO.21.02188","article-title":"Addition of navitoclax to ongoing ruxolitinib therapy in patients with myelofibrosis with progression or suboptimal response: Phase II safety and efficacy","volume":"40","author":"Harrison","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.12.014_bib0067","doi-asserted-by":"crossref","first-page":"E434","DOI":"10.1016\/S2352-3026(22)00116-8","article-title":"Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study","volume":"9","author":"Pemmaraju","year":"2022","journal-title":"Lancet Haematol"},{"issue":"Suppl. 1","key":"10.1016\/j.clml.2022.12.014_bib0068","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1182\/blood-2020-139247","article-title":"A phase 3, open-label, randomized study evaluating the efficacy and safety of navitoclax plus ruxolitinib versus best available therapy in patients with relapsed\/refractory myelofibrosis (TRANSFORM-2)","volume":"136","author":"Dilley","year":"2020","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.clml.2022.12.014_bib0069","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood-2022-160384","article-title":"Efficacy and safety of add-on\u201d parsaclisib to ruxolitinib therapy in myelofibrosis patients with suboptimal response to ruxolitinib: Final results from a phase 2 study","volume":"140","author":"Yacoub","year":"2022","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.clml.2022.12.014_bib0070","first-page":"4225","article-title":"Combination treatment with an MDM2 antagonist and a BET inhibitor targets both myelofibrosis hematopoietic stem\/progenitor cells and their tumor promoting microenvironment","volume":"130","author":"Lu","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.12.014_bib0071","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/bloodadvances.2016000208","article-title":"Targeted deep sequencing in primary myelofibrosis","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv"},{"issue":"Suppl. 1","key":"10.1016\/j.clml.2022.12.014_bib0072","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood-2020-134262","article-title":"An open-label, global, multicenter phase 1b\/2 study of KRT-232, a first-in-class, oral small-molecule inhibitor of murine double minute 2 (MDM2), combined with ruxolitinib in patients who have myelofibrosis and a suboptimal response to ruxolitinib","volume":"136","author":"Mascarenhas","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2022.12.014_bib0073","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/PPO.0000000000000570","article-title":"Combining isocitrate dehydrogenase inhibitors with existing regimens in acute myeloid leukemia","volume":"28","author":"Lachowiez","year":"2022","journal-title":"Cancer J"},{"key":"10.1016\/j.clml.2022.12.014_bib0074","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1172\/JCI94516","article-title":"JAK2\/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition","volume":"128","author":"McKenney","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clml.2022.12.014_bib0075","doi-asserted-by":"crossref","first-page":"5336","DOI":"10.1182\/bloodadvances.2020001528","article-title":"Outcome of patients with IDH1\/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors","volume":"4","author":"Chifotides","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2022.12.014_bib0076","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1111\/bjh.16709","article-title":"Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib","volume":"190","author":"Patel","year":"2020","journal-title":"Br J Haematol"},{"issue":"Suppl. 1","key":"10.1016\/j.clml.2022.12.014_bib0077","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1182\/blood-2022-164678","article-title":"Molecularly targeted combination therapy for advanced phase myeloproliferative neoplasm: MPN-RC 119","volume":"140","author":"Bar-Natan","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.12.014_bib0078","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-021-01157-4","article-title":"Momelotinib: An emerging treatment for myelofibrosis patients with anemia","volume":"15","author":"Chifotides","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2022.12.014_bib0079","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1182\/blood-2016-09-740092","article-title":"Momelotinib inhibits ACVR1\/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents","volume":"129","author":"Asshoff","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.12.014_bib0080","first-page":"4282","article-title":"ACVR1\/JAK1\/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial","volume":"4","author":"Oh","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.12.014_bib0081","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","article-title":"SIMPLIFY-1: A phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor-na\u00efve patients with myelofibrosis","volume":"35","author":"Mesa","year":"2017","journal-title":"J Clin Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.clml.2022.12.014_bib0082","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood-2020-135872","article-title":"Robust overall survival and sustained efficacy outcomes during long term exposure to momelotinib in JAK inhibitor na\u00efve and previously JAK inhibitor treated intermediate\/high risk myelofibrosis patients","volume":"136","author":"Verstovsek","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.12.014_bib0083","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S2352-3026(17)30237-5","article-title":"Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): A randomized, open-label, phase 3 trial","volume":"5","author":"Harrison","year":"2018","journal-title":"Lancet Haematol"},{"issue":"Suppl. 1","key":"10.1016\/j.clml.2022.12.014_bib0084","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1182\/blood-2019-122506","article-title":"Dynamic and time-to-event analyses demonstrate marked reduction in transfusion requirements for Janus kinase inhibitor-na\u00efve myelofibrosis patients treated with momelotinib compared head-to-head with ruxolitinib","volume":"134","author":"Mesa","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.12.014_bib0085","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1080\/10428194.2022.2043304","article-title":"Momelotinib reduces transfusion requirements in patients with myelofibrosis","volume":"63","author":"Mesa","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.12.014_bib0086","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1038\/s41375-022-01637-7","article-title":"Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis","volume":"36","author":"Mesa","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.12.014_bib0087","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2217\/fon-2020-1048","article-title":"MOMENTUM: Momelotinib vs. danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic","volume":"17","author":"Verstovsek","year":"2021","journal-title":"Future Oncol"},{"issue":"10373","key":"10.1016\/j.clml.2022.12.014_bib0088","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0140-6736(22)02036-0","article-title":"Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): Results from an international, double-blind, randomised, controlled phase 3 study","volume":"401","author":"Verstovsek","year":"2023","journal-title":"The Lancet"},{"issue":"Suppl.1","key":"10.1016\/j.clml.2022.12.014_bib0089","doi-asserted-by":"crossref","first-page":"6803","DOI":"10.1182\/blood-2022-162877","article-title":"Transfusion independence response as a potential surrogate for overall survival in JAKi-experienced patients with myelofibrosis from MOMENTUM","volume":"140","author":"Verstovsek","year":"2022","journal-title":"Blood"},{"issue":"16 Suppl","key":"10.1016\/j.clml.2022.12.014_bib0090","doi-asserted-by":"crossref","first-page":"7061","DOI":"10.1200\/JCO.2022.40.16_suppl.7061","article-title":"Thrombocytopenic myelofibrosis (MF) patients previously treated with a JAK inhibitor in a phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) [MOMENTUM]","volume":"40","author":"Gerds","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.12.014_bib0091","first-page":"S215","article-title":"KRT-232, a first-in-class, murine double minute 2 inhibitor (MDM2i), for myelofibrosis (MF) relapsed or refractory (R\/R) to Janus-associated kinase inhibitor (JAKi) treatment","volume":"4","author":"Al-Ali","year":"2020","journal-title":"HemaSphere"},{"issue":"Suppl. 1","key":"10.1016\/j.clml.2022.12.014_bib0092","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1182\/blood-2021-147543","article-title":"Potential disease-modifying activity of navtemadlin (KRT-232), a first-in-class MDM2 inhibitor, correlates with clinical benefits in relapsed\/refractory myelofibrosis","volume":"138","author":"Vachhani","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.12.014_bib0093","doi-asserted-by":"crossref","DOI":"10.2217\/fon-2022-0901","article-title":"BOREAS: A global phase III study of the MDM2 inhibitor navtemadlin KRT-232 in relapsed\/refractory myelofibrosis","author":"Verstovsek","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.clml.2022.12.014_bib0094","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1200\/JCO.20.02864","article-title":"Randomized, single-blind, multicenter phase II study of two doses of imetelstat in relapsed or refractory myelofibrosis","volume":"39","author":"Mascarenhas","year":"2021","journal-title":"J Clin Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.clml.2022.12.014_bib0095","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2020-138818","article-title":"Potential disease-modifying activity of imetelstat demonstrated by reduction in cytogenetically abnormal clones and mutation burden leads to clinical benefits in relapsed\/refractory myelofibrosis patients","volume":"136","author":"Mascarenhas","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.12.014_bib0096","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00277-021-04683-w","article-title":"Favorable overall survival with imetelstat in relapsed\/refractory myelofibrosis patients compared with real world data","volume":"101","author":"Kuykendall","year":"2022","journal-title":"Ann. Haematol"},{"issue":"7","key":"10.1016\/j.clml.2022.12.014_bib0097","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","article-title":"Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis","volume":"124","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.12.014_bib0098","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"issue":"Suppl. 1","key":"10.1016\/j.clml.2022.12.014_bib0099","first-page":"508;","article-title":"Imetelstat treatment results in clinical benefits, including improved overall survival, in patients with higher-risk triple-negative myelofibrosis relapsed\/refractory to Janus kinase inhibitors (JAKi)","volume":"4","author":"Kiladjian","year":"2020","journal-title":"HemaSphere"},{"key":"10.1016\/j.clml.2022.12.014_bib0100","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.2217\/fon-2022-0235","article-title":"Imetelstat in intermediate-2 or high-risk myelofibrosis (MF) refractory to Janus kinase inhibitor: IMpactMF phase III study design","volume":"18","author":"Mascarenhas","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.clml.2022.12.014_bib0101","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13045-020-00995-y","article-title":"Novel therapeutics in myeloproliferative neoplasms","volume":"13","author":"Venugopal","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.clml.2022.12.014_bib0102","doi-asserted-by":"crossref","first-page":"9670","DOI":"10.1182\/blood-2022-162543","article-title":"Momelotinib (MMB) long-term safety: pooled data from three phase 3 randomized-controlled trials (RCTs)","volume":"140","author":"Verstovsek","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.12.014_bib0103","doi-asserted-by":"crossref","first-page":"129","DOI":"10.36401\/JIPO-20-36","article-title":"JAK be nimble: Reviewing the development of JAK inhibitors and JAK inhibitor combinations for special populations of patients with myelofibrosis","volume":"4","author":"Kuykendall","year":"2021","journal-title":"J Immun Precision Oncol"},{"key":"10.1016\/j.clml.2022.12.014_bib0104","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1200\/JCO.21.02246","article-title":"Disease modification in myelofibrosis: an elusive goal?","volume":"40","author":"Vachhani","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.12.014_bib0105","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1002\/cncr.34205","article-title":"Defining disease modification in myelofibrosis in the era of targeted therapy","volume":"128","author":"Pemmaraju","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2022.12.014_bib115","doi-asserted-by":"crossref","first-page":"e778","DOI":"10.1097\/HS9.0000000000000778","article-title":"Treating anemic patients with myelofibrosis in the new Janus kinase inhibitor era: Current evidence and real-world implications","volume":"30","author":"Gerds","year":"2022","journal-title":"HemaSphere"},{"key":"10.1016\/j.clml.2022.12.014_bib0106","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41375-022-01767-y","article-title":"Biological drivers of clinical phenotype in myelofibrosis","volume":"37","author":"Mascarenhas","year":"2022","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.clml.2022.12.014_bib118","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1080\/17474086.2022.2112565","article-title":"Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia","volume":"15","author":"Mascarenhas","year":"2022","journal-title":"Exp Review Hematol"},{"issue":"Suppl. 1","key":"10.1016\/j.clml.2022.12.014_bib116","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1182\/blood-2022-159435","article-title":"Discovery of INCA033989, a monoclonal antibody that selectively antagonizes mutant calreticulin oncogenic function in myeloproliferative neoplasms","volume":"140","author":"Reis","year":"2022","journal-title":"Blood"},{"issue":"649","key":"10.1016\/j.clml.2022.12.014_bib117","doi-asserted-by":"crossref","first-page":"eaba4380","DOI":"10.1126\/scitranslmed.aba4380","article-title":"Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine","volume":"14","author":"Gigoux","year":"2022","journal-title":"Sci Trans Med"},{"key":"10.1016\/j.clml.2022.12.014_bib0107","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.637420","article-title":"Therapeutic cancer vaccination with a peptide derived from the calreticulin exon 9 mutations induces strong cellular immune responses in patients with CALR-mutant chronic myeloproliferative neoplasms","volume":"11","author":"Handlos Grauslund","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2022.12.014_bib0108","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.3390\/cancers12071763","article-title":"Cancer immune therapy for Philadelphia chromosome-negative chronic myeloproliferative neoplasms","volume":"12","author":"Holmstr\u00f6m","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2022.12.014_bib0109","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/leu.2017.214","article-title":"The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy","volume":"32","author":"Holmstr\u00f6m","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.12.014_bib0110","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/leu.2016.290","article-title":"The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms","volume":"31","author":"Holmstr\u00f6m","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.12.014_bib0111","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1158\/2159-8290.CD-18-1356","article-title":"Immune checkpoint blockade enhances shared neoantigen-induced T cell immunity directed against mutated calreticulin in myeloproliferative neoplasms","volume":"9","author":"Cimen-Bozkus","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clml.2022.12.014_bib0112","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202152904","article-title":"Targeting human CALR-mutated MPN progenitors with a neoepitope-directed monoclonal antibody","volume":"23","author":"Tvorogov","year":"2022","journal-title":"EMBO Reports"},{"key":"10.1016\/j.clml.2022.12.014_bib0113","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood.2019000622","article-title":"Mutant calreticulin in myeloproliferative neoplasms","volume":"134","author":"How","year":"2019","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022017785?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022017785?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:41:21Z","timestamp":1761871281000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022017785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":116,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S2152265022017785"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.12.014","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions: Novel Therapeutic Strategies in Development for Myelofibrosis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}